Reply to F. Tomao et al

Affiliations

¹ Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.

Comment

Patrick A Ott et al. J Clin Oncol. 2017.

. 2017 Nov 1;35(31):3633-3634.

doi: 10.1200/JCO.2017.74.8681. Epub 2017 Sep 7.

¹ Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.

No abstract available

Comment on

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. Ott PA, et al. J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489510 Clinical Trial.
Pembrolizumab in Programmed Death Ligand 1-Positive Endometrial Cancer.
Tomao F, Panici PB, Tomao S. Tomao F, et al. J Clin Oncol. 2017 Nov 1;35(31):3633. doi: 10.1200/JCO.2017.74.4987. Epub 2017 Sep 7. J Clin Oncol. 2017. PMID: 28880747 No abstract available.